

Glioblastoma Multiforme Treatment Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/G072ACCA0AFCEN.html>

Date: March 2022

Pages: 68

Price: US\$ 3,250.00 (Single User License)

ID: G072ACCA0AFCEN

Abstracts

This report contains market size and forecasts of Glioblastoma Multiforme Treatment in Global, including the following market information:

Global Glioblastoma Multiforme Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Glioblastoma Multiforme Treatment market was valued at 564.1 million in 2021 and is projected to reach US\$ 990.5 million by 2028, at a CAGR of 8.4% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Bevacizumab (Avastin) Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Glioblastoma Multiforme Treatment include AbbVie, Inc, Activartis GmbH, Agenus Inc, Arog Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Cavion LLC, Celldex Therapeutics Inc, Cortice Biosciences and Exelixis Inc and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Glioblastoma Multiforme Treatment companies, and industry experts on this industry, involving the revenue,

demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Glioblastoma Multiforme Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Glioblastoma Multiforme Treatment Market Segment Percentages, by Type, 2021 (%)

Bevacizumab (Avastin)

Carmustine (BiCNU)

Temozolomide (Temodar and Temodal and Temcad)

Global Glioblastoma Multiforme Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Glioblastoma Multiforme Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Others

Global Glioblastoma Multiforme Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Glioblastoma Multiforme Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Glioblastoma Multiforme Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Glioblastoma Multiforme Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AbbVie, Inc

Activartis GmbH

Agenus Inc

Arog Pharmaceuticals, Inc

Bristol-Myers Squibb Company

Cavion LLC

Celldex Therapeutics Inc

Cortice Biosciences

Exelixis Inc

F. Hoffmann-La Roche Ltd.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Glioblastoma Multiforme Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Glioblastoma Multiforme Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT OVERALL MARKET SIZE

- 2.1 Global Glioblastoma Multiforme Treatment Market Size: 2021 VS 2028
- 2.2 Global Glioblastoma Multiforme Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Glioblastoma Multiforme Treatment Players in Global Market
- 3.2 Top Global Glioblastoma Multiforme Treatment Companies Ranked by Revenue
- 3.3 Global Glioblastoma Multiforme Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Glioblastoma Multiforme Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Glioblastoma Multiforme Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Glioblastoma Multiforme Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Glioblastoma Multiforme Treatment Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Glioblastoma Multiforme Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Glioblastoma Multiforme Treatment Market Size Markets, 2021 & 2028

4.1.2 Bevacizumab (Avastin)

4.1.3 Carmustine (BiCNU)

4.1.4 Temozolomide (Temodar and Temodal and Temcad)

4.2 By Type - Global Glioblastoma Multiforme Treatment Revenue & Forecasts

4.2.1 By Type - Global Glioblastoma Multiforme Treatment Revenue, 2017-2022

4.2.2 By Type - Global Glioblastoma Multiforme Treatment Revenue, 2023-2028

4.2.3 By Type - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Glioblastoma Multiforme Treatment Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Glioblastoma Multiforme Treatment Revenue & Forecasts

5.2.1 By Application - Global Glioblastoma Multiforme Treatment Revenue, 2017-2022

5.2.2 By Application - Global Glioblastoma Multiforme Treatment Revenue, 2023-2028

5.2.3 By Application - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Glioblastoma Multiforme Treatment Market Size, 2021 & 2028

6.2 By Region - Global Glioblastoma Multiforme Treatment Revenue & Forecasts

6.2.1 By Region - Global Glioblastoma Multiforme Treatment Revenue, 2017-2022

6.2.2 By Region - Global Glioblastoma Multiforme Treatment Revenue, 2023-2028

6.2.3 By Region - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.3.2 US Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.3.3 Canada Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.3.4 Mexico Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.4.2 Germany Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.3 France Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.4 U.K. Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.5 Italy Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.6 Russia Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.4.8 Benelux Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.5.2 China Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5.3 Japan Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5.4 South Korea Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.5.6 India Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.6.2 Brazil Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.6.3 Argentina Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Glioblastoma Multiforme Treatment Revenue, 2017-2028

6.7.2 Turkey Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.7.3 Israel Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Glioblastoma Multiforme Treatment Market Size, 2017-2028

6.7.5 UAE Glioblastoma Multiforme Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AbbVie, Inc

7.1.1 AbbVie, Inc Corporate Summary

7.1.2 AbbVie, Inc Business Overview

7.1.3 AbbVie, Inc Glioblastoma Multiforme Treatment Major Product Offerings

7.1.4 AbbVie, Inc Glioblastoma Multiforme Treatment Revenue in Global Market

(2017-2022)

7.1.5 AbbVie, Inc Key News

7.2 Activartis GmbH

7.2.1 Activartis GmbH Corporate Summary

7.2.2 Activartis GmbH Business Overview

7.2.3 Activartis GmbH Glioblastoma Multiforme Treatment Major Product Offerings

7.2.4 Activartis GmbH Glioblastoma Multiforme Treatment Revenue in Global Market

(2017-2022)

7.2.5 Activartis GmbH Key News

7.3 Agenus Inc

7.3.1 Agenus Inc Corporate Summary

7.3.2 Agenus Inc Business Overview

7.3.3 Agenus Inc Glioblastoma Multiforme Treatment Major Product Offerings

7.3.4 Agenus Inc Glioblastoma Multiforme Treatment Revenue in Global Market

(2017-2022)

7.3.5 Agenus Inc Key News

7.4 Arog Pharmaceuticals, Inc

7.4.1 Arog Pharmaceuticals, Inc Corporate Summary

7.4.2 Arog Pharmaceuticals, Inc Business Overview

7.4.3 Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Major Product Offerings

7.4.4 Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.4.5 Arog Pharmaceuticals, Inc Key News

7.5 Bristol-Myers Squibb Company

7.5.1 Bristol-Myers Squibb Company Corporate Summary

7.5.2 Bristol-Myers Squibb Company Business Overview

7.5.3 Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Major Product Offerings

7.5.4 Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.5.5 Bristol-Myers Squibb Company Key News

7.6 Cavion LLC

7.6.1 Cavion LLC Corporate Summary

7.6.2 Cavion LLC Business Overview

7.6.3 Cavion LLC Glioblastoma Multiforme Treatment Major Product Offerings

7.6.4 Cavion LLC Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.6.5 Cavion LLC Key News

7.7 Celldex Therapeutics Inc

7.7.1 Celldex Therapeutics Inc Corporate Summary

7.7.2 Celldex Therapeutics Inc Business Overview

7.7.3 Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Major Product Offerings

7.7.4 Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.7.5 Celldex Therapeutics Inc Key News

7.8 Cortice Biosciences

7.8.1 Cortice Biosciences Corporate Summary

7.8.2 Cortice Biosciences Business Overview

7.8.3 Cortice Biosciences Glioblastoma Multiforme Treatment Major Product Offerings

7.8.4 Cortice Biosciences Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.8.5 Cortice Biosciences Key News

7.9 Exelixis Inc

7.9.1 Exelixis Inc Corporate Summary

7.9.2 Exelixis Inc Business Overview

7.9.3 Exelixis Inc Glioblastoma Multiforme Treatment Major Product Offerings

7.9.4 Exelixis Inc Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.9.5 Exelixis Inc Key News

7.10 F. Hoffmann-La Roche Ltd.

7.10.1 F. Hoffmann-La Roche Ltd. Corporate Summary

7.10.2 F. Hoffmann-La Roche Ltd. Business Overview

7.10.3 F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Major Product Offerings

7.10.4 F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)

7.10.5 F. Hoffmann-La Roche Ltd. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Glioblastoma Multiforme Treatment Market Opportunities & Trends in Global Market

Table 2. Glioblastoma Multiforme Treatment Market Drivers in Global Market

Table 3. Glioblastoma Multiforme Treatment Market Restraints in Global Market

Table 4. Key Players of Glioblastoma Multiforme Treatment in Global Market

Table 5. Top Glioblastoma Multiforme Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Glioblastoma Multiforme Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Glioblastoma Multiforme Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Glioblastoma Multiforme Treatment Product Type

Table 9. List of Global Tier 1 Glioblastoma Multiforme Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Glioblastoma Multiforme Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Glioblastoma Multiforme Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Glioblastoma Multiforme Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Glioblastoma Multiforme Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Glioblastoma Multiforme Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Glioblastoma Multiforme Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Glioblastoma Multiforme Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Glioblastoma Multiforme Treatment Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. AbbVie, Inc Corporate Summary

Table 31. AbbVie, Inc Glioblastoma Multiforme Treatment Product Offerings

Table 32. AbbVie, Inc Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Activartis GmbH Corporate Summary

Table 34. Activartis GmbH Glioblastoma Multiforme Treatment Product Offerings

Table 35. Activartis GmbH Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Agenus Inc Corporate Summary

Table 37. Agenus Inc Glioblastoma Multiforme Treatment Product Offerings

Table 38. Agenus Inc Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Arog Pharmaceuticals, Inc Corporate Summary

Table 40. Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Product Offerings

Table 41. Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Bristol-Myers Squibb Company Corporate Summary

Table 43. Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Product Offerings

Table 44. Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Cavion LLC Corporate Summary

Table 46. Cavion LLC Glioblastoma Multiforme Treatment Product Offerings

Table 47. Cavion LLC Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Celldex Therapeutics Inc Corporate Summary

Table 49. Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Product Offerings

Table 50. Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Cortice Biosciences Corporate Summary

Table 52. Cortice Biosciences Glioblastoma Multiforme Treatment Product Offerings

Table 53. Cortice Biosciences Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Exelixis Inc Corporate Summary

Table 55. Exelixis Inc Glioblastoma Multiforme Treatment Product Offerings

Table 56. Exelixis Inc Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. F. Hoffmann-La Roche Ltd. Corporate Summary

Table 58. F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Product Offerings

Table 59. F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Glioblastoma Multiforme Treatment Segment by Type in 2021
- Figure 2. Glioblastoma Multiforme Treatment Segment by Application in 2021
- Figure 3. Global Glioblastoma Multiforme Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Glioblastoma Multiforme Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Glioblastoma Multiforme Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Glioblastoma Multiforme Treatment Revenue in 2021
- Figure 8. By Type - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 12. US Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
- Figure 24. China Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Glioblastoma Multiforme Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. AbbVie, Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Activartis GmbH Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Agenus Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Cavion LLC Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Cortice Biosciences Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Exelixis Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Glioblastoma Multiforme Treatment Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/G072ACCA0AFCEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G072ACCA0AFCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970